Investigation of Curcumin on symptoms of knee osteoarthritis: a two months, double blind, Placebo-controlled, randomized pilot study

• Conditions: M19.09

• Registration Number: DRKS00022789
• Lead Sponsor: Wacker Chemie AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-08-06
• Study Completion: 2021-03-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Women and men with painful knee joints e.g. defined as e.g. WOMAC pain score part A + stiffness score part B at least 15 points;
Volunteers with primary osteoarthritis who are not expected to require surgical treatment for at least three months after inclusion;
Known X-ray finding (Kellgren score of 1 to 3; X-ray not older than 24 months);
Discomfort over a period of at least 3 months

Exclusion Criteria

BMI = 32 kg/m2, Medical treatment of joint disease besides Paracetamol as analgesic medication for emergency treatment; Inflammatory, infectious or metabolic joint disorder; Artificial joint replacement in knees or hip; Surgery within the last 6 months in knees or hip; Intra-articular therapy within the last 3 months; Oral cartilage treatment within the last 3 months

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sum score of Pain and Stiffness (Part A + Part B WOMAC score) after 4 and 8 weeks.

Secondary Outcome Measures

Name	Time	Method
After 8 weeks: Part A, B, C WOMAC; KOOS quality of life; KOOS sport and recreation; <br>Performance-based tests (30s chair stand test, 40m fast-paced walk test, stair climb test); <br>Global assessment; <br>Reduction of analgetic medication; <br>SF-36; <br>Inflammatory markers (e.g. hs-CRP, cytokine panel)